deferoxamine has been researched along with Hematologic Neoplasms in 4 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To verify efficacy and tolerability of deferoxamine by subcutaneous bolus injection as compared to the conventional pump-driven slow infusion, eleven patients affected by oncohematologic diseases were given 2 g of deferoxamine diluted in 10 mL of distilled water over twelve hours by continuous infusion, or by bolus injection in two divided doses." | 7.70 | Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. ( Aprili, G; Borgna-Pignatti, C; De Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 1998) |
| "To verify efficacy and tolerability of deferoxamine by subcutaneous bolus injection as compared to the conventional pump-driven slow infusion, eleven patients affected by oncohematologic diseases were given 2 g of deferoxamine diluted in 10 mL of distilled water over twelve hours by continuous infusion, or by bolus injection in two divided doses." | 3.70 | Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. ( Aprili, G; Borgna-Pignatti, C; De Gironcoli, M; Franchini, M; Gandini, G; Vassanelli, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SH | 1 |
| Soh, H | 1 |
| Chung, JH | 1 |
| Cho, EH | 1 |
| Lee, SJ | 2 |
| Ju, JM | 1 |
| Sheen, JH | 1 |
| Kim, H | 1 |
| Oh, SJ | 1 |
| Chung, J | 1 |
| Choi, K | 1 |
| Kim, SY | 1 |
| Ryu, JS | 1 |
| Sivgin, S | 1 |
| Eser, B | 1 |
| Ng, PP | 1 |
| Helguera, G | 1 |
| Daniels, TR | 1 |
| Lomas, SZ | 1 |
| Rodriguez, JA | 1 |
| Schiller, G | 1 |
| Bonavida, B | 1 |
| Morrison, SL | 1 |
| Penichet, ML | 1 |
| Borgna-Pignatti, C | 1 |
| Franchini, M | 1 |
| Gandini, G | 1 |
| Vassanelli, A | 1 |
| De Gironcoli, M | 1 |
| Aprili, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.[NCT00469560] | Phase 3 | 158 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Hematologic Neoplasms
| Article | Year |
|---|---|
The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: where do we stand?
Topics: Animals; Antimicrobial Cationic Peptides; Deferoxamine; Hematologic Neoplasms; Hematology; Hematopoi | 2013 |
3 other studies available for deferoxamine and Hematologic Neoplasms
| Article | Year |
|---|---|
Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging.
Topics: Cell Proliferation; Cell Survival; Deferoxamine; Hematologic Neoplasms; Humans; Immunoconjugates; Is | 2020 |
Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Avidin; Caspase Inhibitors; Cell Line, Tumor; Cell Proli | 2006 |
Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
Topics: Adult; Aged; Chelating Agents; Chelation Therapy; Deferoxamine; Female; Hematologic Diseases; Hemato | 1998 |